These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

177 related items for PubMed ID: 10123271

  • 1. Clinical appropriateness, therapeutic equivalence, and cost of conversion of H2 antagonist therapy.
    Kitrenos JG, Brown DR, Letting DJ, Rotella DL.
    Hosp Formul; 1993 Jan; 28(1):86-8, 91, 95-6. PubMed ID: 10123271
    [Abstract] [Full Text] [Related]

  • 2. Multi-purpose evaluation of H2-antagonist usage.
    Gianarkis D.
    Hosp Formul; 1992 May; 27(5):527-30, 532. PubMed ID: 10117769
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Multidisciplinary education ensures successful formulary conversion.
    Barfield PS, Amerson AB.
    Hosp Formul; 1991 Nov; 26 Suppl D():28-9. PubMed ID: 10136563
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Retrospective analysis of formulary restriction demonstrates significant cost savings.
    Wetmore RW, Jennings RH.
    Hosp Formul; 1991 Nov; 26 Suppl D():30-2. PubMed ID: 10136564
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Formulary designation of cimetidine as the primary intravenous histamine H2-receptor antagonist.
    Berkowitz HS.
    Am J Hosp Pharm; 1992 Jan; 49(1):134-5. PubMed ID: 1349201
    [No Abstract] [Full Text] [Related]

  • 9. Experience with a two-tiered therapeutic interchange policy.
    Rich DS.
    Am J Hosp Pharm; 1989 Sep; 46(9):1792-8. PubMed ID: 2572167
    [Abstract] [Full Text] [Related]

  • 10. Antiulcer therapy: an exercise in formulary management.
    Foulke GE, Siepler J.
    J Clin Gastroenterol; 1990 Sep; 12 Suppl 2():S64-8. PubMed ID: 1978846
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Use of concurrent monitoring and a preprinted note to modify prescribing of i.v. cimetidine and ranitidine in a teaching hospital.
    Dannenhoffer MA, Slaughter RL, Hunt SN.
    Am J Hosp Pharm; 1989 Aug; 46(8):1570-5. PubMed ID: 2773962
    [Abstract] [Full Text] [Related]

  • 13. Bar-code technology applied to drug-use evaluation.
    Zarowitz BJ, Petitta A, Mlynarek M, Touchette M, Peters M, Long P, Patel R.
    Am J Hosp Pharm; 1993 May; 50(5):935-9. PubMed ID: 8099468
    [Abstract] [Full Text] [Related]

  • 14. Reducing costs with formulary limitation of H2-receptor antagonists in a community hospital.
    Coppola P.
    Hosp Pharm; 1991 Feb; 26(2):126-9, 142. PubMed ID: 10136547
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Effect of a criteria-based cost-containment program on the selection of oral H2-receptor antagonists.
    Falbe WJ, Bess DT, Capers CC, Haymond JD, Stahl AA.
    Am J Hosp Pharm; 1992 Mar; 49(3):632-3. PubMed ID: 1598944
    [No Abstract] [Full Text] [Related]

  • 17. Achieving rational therapeutics through consensus-based protocols and follow-up.
    Quintiliani R, Gousse GC, Chow MS.
    Hosp Formul; 1990 Mar; 25(3):283-4, 289-94. PubMed ID: 10103836
    [Abstract] [Full Text] [Related]

  • 18. A pharmacoeconomic analysis of IV H2-receptor antagonist use in 40 hospitals.
    Segal R, Oh T, Ben-Joseph R, Russell WL.
    Hosp Formul; 1994 May; 29(5):379-82, 388-91. PubMed ID: 10136601
    [Abstract] [Full Text] [Related]

  • 19. Savings achieved through cephalosporin surveillance.
    Katz E, Schlamowitz S.
    Am J Hosp Pharm; 1978 Dec; 35(12):1521-3. PubMed ID: 717407
    [Abstract] [Full Text] [Related]

  • 20. Therapeutic-interchange program for oral histamine H2-receptor antagonists.
    Chase SL, Peterson AM, Wordell CJ.
    Am J Health Syst Pharm; 1998 Jul 01; 55(13):1382-6. PubMed ID: 9659966
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.